Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
P/E ratio for Kezar Life Sciences, Inc. (KZR)
P/E ratio as of 2023: -6.74
According to Kezar Life Sciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.74. At the end of 2022 the company had a P/E ratio of -72.61.
P/E ratio history for Kezar Life Sciences, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.74 |
| 2022 | -72.61 |
| 2021 | -165.57 |
| 2020 | -58.91 |
| 2019 | -24.27 |
| 2018 | -104.56 |
| 2017 | -271.36 |
| 2016 | -257.08 |